LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Biologics/Stem Cells Treat Achilles Tendon Injury
Biologics

Stem Cells Treat Achilles Tendon Injury

October 9, 2014 2 min read Premium comments

Advertisement

Stem Cells Treat Achilles Tendon Injury
Bioologic Therapies / Dr. Wade McKenna / Neil Riordan, Ph.D.
Secondary

In a “first” for stem cell therapy, the Ocala, Florida based Biologic Therapies, Inc. successfully treated a patient’s chronically injured Achilles tendon with an injection of stem cells. Biologic Therapies’ Chief Medical Director R. Wade McKenna, M.D. and Chief Scientific Officer Neil H. Riordan, M.D. founders of the Riordan-McKenna Institute in Southlake, Texas, authored the report titled ‘Minimally Invasive Autologous Bone Marrow Concentrate Stem Cells in the Treatment of the Chronically Injured Achilles Tendon: A Case Report” The journal, CELLR4, the official journal of The Cure Alliance, published the report.

The case involved a 56-year-old patient who complained about a painful “knot” in her left Achilles tendon. She had been an active tennis player and recreational athlete, but had not been able to play tennis or jog for ten years. She experienced severe pain when walking. She had been to multiple physicians and had followed ten years of standard treatment with stretches and anti-inflammatories. She had refused multiple offers of invasive surgery that could not promise a return to tennis.

On physical examination McKenna found that the patient had a large, palpable knot in the Achilles tendon. An MRI scan showed severe hypertrophic changes with marked tendinopathy.

The patient received stem cell therapy in the doctor’s office. McKenna drew bone marrow from the patient’s tibia, processed it in a centrifuge to concentrate the stem cells and growth factors and then injected the mixture around the patient’s injured tendon. McKenna had given the patient an injection of local anesthesia and she reported little or not pain during the procedure.

After six weeks the patient reported no pain at rest and minimal pain while walking. After eight weeks, there was less pain while walking. The knot had shrunk to less than 50% of the pre-treatment size and was relatively non-tender to touch. The patient was playing tennis without significant pain or difficulty. After ten weeks an MRI scan showed even more reduction in the size of the knot, and pain was reduced even further. After 32 weeks an MRI scan showed near complete healing of the treated Achilles tendon.

According to Luke Whalen, Biologic Therapies’ CEO, “This is an extremely important development for Biologic Therapies. The case report shows that stem cell therapy is an effective treatment for chronic Achilles tendon injury, which has not been documented before. The report also shows that stem cell therapy for this type of injury can be administered in a physician’s office as a point-of-care outpatient procedure using Biologic Therapies products. There is no need for hospitalization and surgery as would have been the case previously.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy